Topas Therapeutics and Boehringer Ingelheim Sign Multi-Year Collaboration and Option Agreement
In All, PortfolioCompanies join forces in immune tolerance to tackle ADA (anti-drug antibodies) Initial focus on next generation vector-based therapeutics Boehringer Ingelheim is granted option to in-license several pre-clinical development candidates produced under the collaboration Hamburg, 24th April 2018 – Topas Therapeutics GmbH (Topas), a Hamburg,…